SCHEMBL18296100

SCHEMBL18296100

NC(=O)c1ccc(C2CC2)cc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.47
▸ SLC6A2 P23975 4/20 0.43
▸ SLC6A4 P31645 4/20 0.43
▸ SLC6A3 Q01959 4/20 0.43
▸ MKNK1 Q9BUB5 1/20 0.42
▸ MKNK2 Q9HBH9 1/20 0.42
▸ SMURF2 Q9HAU4 1/20 0.41
▸ SMURF1 Q9HCE7 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ ACMSD Q8TDX5 2/20 0.40
▸ MRGPRX4 Q96LA9 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA3 P07451 1/20 0.39
▸ CA4 P22748 1/20 0.39
▸ CA6 P23280 1/20 0.39
▸ CA5A P35218 1/20 0.39
▸ CA7 P43166 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1785217 0.86 NPSR1 (0.45) KMT2ASLC6A2SLC6A4SLC6A3SMURF2
SCHEMBL13544473 0.84 TSHR (0.55) SLC6A2SLC6A4SLC6A3SMURF2SMURF1
SCHEMBL18296122 0.84 SMURF2 (0.42) SLC6A2SLC6A4SLC6A3SMURF2SMURF1
SCHEMBL18075472 0.82 SMURF2 (0.44) SLC6A2SLC6A4SLC6A3SMURF2SMURF1
SCHEMBL21434787 0.81 MAPT (0.60) SMURF2SMURF1MRGPRX4HPGDKDM4E
SCHEMBL1787918 0.79 ACMSD (0.53) KMT2ASLC6A2SLC6A4SLC6A3ATM
SCHEMBL3375579 0.79 DGAT1 (0.53) MKNK2ACMSDCYP2C9
SCHEMBL29439363 0.79 DGAT1 (0.53) MKNK2ACMSDCYP2C9
SCHEMBL17261759 0.78 SMURF2 (0.41) SMURF2SMURF1ACMSDMRGPRX4CYP2C9
SCHEMBL3576543 0.78 SLC6A3 (0.46) KMT2ASLC6A2SLC6A4SLC6A3SMURF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503467-B2 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2025-12-23 — — US disclosed
CN-119528824-A 2-Oxo quinazoline derivatives as methionine adenosyltransferase 2A inhibitors 伊迪亚生物科学有限公司 2025-02-28 — — CN disclosed
CN-113166078-B 2-Oxo quinazoline derivatives as methionine adenosyltransferase 2A inhibitors 伊迪亚生物科学有限公司 2024-11-19 — — CN disclosed
US-20220106276-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. 2022-04-07 — — US disclosed
EP-3894396-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS Ideaya Biosciences, Inc. (US) 2021-10-20 — — EP disclosed
US-11130759-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCE, INC. (US) 2021-09-28 — — US disclosed
US-11084798-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2021-08-10 — — US disclosed
CN-113166078-A 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors 伊迪亚生物科学有限公司 2021-07-23 — — CN disclosed
US-11046691-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2021-06-29 — — US disclosed
WO-2020123395-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2020-06-18 — — WO disclosed
CN-105189456-B Covalent inhibitors of KRAS G12C 亚瑞克西斯制药公司 2017-12-19 — — CN disclosed
WO-2016196776-A2 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS LLC. (US) 2016-12-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11046691-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors MAT2B, MAT2A, MAT1A KMT2A 102/4885SLC6A2 1270/4885SLC6A4 2354/4885
US-11130759-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors MAT2B, MAT2A, MAT1A KMT2A 102/4885SLC6A2 1270/4885SLC6A4 2354/4885
US-11084798-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors MAT2B, MAT2A, MAT1A KMT2A 102/4885SLC6A2 1270/4885SLC6A4 2354/4885
US-20220106276-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS MAT2B, MAT2A, MAT1A KMT2A 102/4885SLC6A2 1270/4885SLC6A4 2354/4885
US-12503467-B2 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors MAT2B, MAT2A, MAT1A KMT2A 102/4885SLC6A2 1270/4885SLC6A4 2354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback